Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06157567 · ClinicalTrials.gov registry record · NA

Clinical Feasibility Study to Evaluate the Safety and Performance of the Profound Matrix System

A NA study of Wrinkle and Skin Laxity, sponsored by Candela Corporation.

Active
Registry status
NA
Development phase
500
Enrollment target
6
Study locations

NCT06157567 is a NA study of Wrinkle and Skin Laxity that is active but no longer recruiting, run by Candela Corporation. The registered enrollment target is 500 participants, above the 100-participant average among 25 other Wrinkle trials with a reported enrollment target (400% higher). The trial reports 6 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06157567, a NA study of Wrinkle and Skin Laxity, is active but no longer recruiting, sponsored by Candela Corporation.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
500 participants
Enrollment target
6
Study locations

Study Summary

This is a non-randomized, multi-center, open-label clinical trial evaluating clinical feasibility treatments with the Profound Matrix system.

Interventions

  • DEVICE Profound Matrix

Study Locations (6)

Other

  • Waterfront Skin and Laser - Vancouver
  • Candela European Institue of Excellence - Madrid

Florida

  • Center for Morden Aesthetic Medicine - Jacksonville

Massachusetts

  • Candela Institue for Excellence - Marlborough

North Carolina

  • Concierge Medical Arts - Fayetteville

Virginia

  • Gerrish MedEsthetics - Vienna

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2022-05-24
Est. Completion 2028-05-24
Phase NA

Sponsor

Candela Corporation

12 total trials

What the Registry Record Tells You About NCT06157567

The ClinicalTrials.gov registry entry for NCT06157567 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 100-participant average among 25 other Wrinkle trials with a reported enrollment target (400% higher). The listed sponsor is Candela Corporation, which has 12 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Wrinkle appearing as the primary indexed condition, and to 1 intervention - of which Profound Matrix is the first listed.

NCT06157567 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Other, Florida, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06157567 about?

NCT06157567 is a clinical study titled "Clinical Feasibility Study to Evaluate the Safety and Performance of the Profound Matrix System". This is a non-randomized, multi-center, open-label clinical trial evaluating clinical feasibility treatments with the Profound Matrix system.

What is the current status of trial NCT06157567?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 500 participants. The study started on 2022-05-24. Estimated completion is 2028-05-24.

What conditions does trial NCT06157567 study?

This clinical trial studies the following conditions: Wrinkle, Skin Laxity, Skin Condition.

What interventions are being tested in trial NCT06157567?

The interventions under investigation include: Profound Matrix (DEVICE).

Who is sponsoring clinical trial NCT06157567?

This trial is sponsored by Candela Corporation, which has 12 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06157567 being conducted?

This trial has 6 study locations across Florida, Massachusetts, North Carolina, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Wrinkle

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.